03:41 AM EDT, 10/29/2026 (MT Newswires) -- Prolight Diagnostics (PRLD.ST) received intention-to-grant notifications from the European Patent Office for two patent applications covering its Psyros single-molecule-counting diagnostics platform, according to a Thursday release. The point-of-care systems developer said the applications cover multiplexing, which enables simultaneous measurement of multiple biomarkers without cross-reactivity, and dynamic range, which allows measurements across biomarker concentrations while maintaining sensitivity. The technologies are complementary and can be combined in diagnostic tests.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.